Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial

[Guest guest]

SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C

Triple Therapy Trial; First Patients

Business Wire Thu, 23 Dec 2004 3:43 AM PST

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals,

Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and

marketing partner for ZADAXIN®, has begun enrolling patients infected with the

hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial

evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha

and

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041223005058 & newsLang=en

[Guest guest]

SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C

Triple Therapy Trial; First Patients

Business Wire Thu, 23 Dec 2004 3:43 AM PST

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals,

Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and

marketing partner for ZADAXIN®, has begun enrolling patients infected with the

hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial

evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha

and

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041223005058 & newsLang=en

[Guest guest]

SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C

Triple Therapy Trial; First Patients

Business Wire Thu, 23 Dec 2004 3:43 AM PST

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals,

Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and

marketing partner for ZADAXIN®, has begun enrolling patients infected with the

hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial

evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha

and

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041223005058 & newsLang=en

[Guest guest]

SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C

Triple Therapy Trial; First Patients

Business Wire Thu, 23 Dec 2004 3:43 AM PST

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals,

Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and

marketing partner for ZADAXIN®, has begun enrolling patients infected with the

hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial

evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha

and

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041223005058 & newsLang=en